Efficacy of immune checkpoint inhibitors in advanced mucosal melanoma: A systematic review and meta-analysis
Authors:
- James P. PhamJPJames P. Pham
- Mickey KondoMKMickey Kondo
- Joshua HurwitzJHJoshua Hurwitz
- Rasha CosmanRCRasha Cosman
- Simone M. GoldingerSGSimone M. Goldinger
- Reinhard DummerReinhard Dummer
- Hao-Wen SimHao-Wen Sim
- Anthony M. JoshuaAJAnthony M. Joshua
Open Access
- 9 October 2025
- journal article
- review article
- Published by Elsevier in EJC Skin Cancer
- Vol. 3
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyAnnals of Oncology, 2022
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022European Journal of Cancer, 2022
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaNew England Journal of Medicine, 2022
- Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)ESMO Open, 2021
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibitionEuropean Journal of Cancer, 2021
- Real‐world outcomes of advanced melanoma patients not represented in phase III trialsInternational Journal of Cancer, 2020
- The mutational landscape of mucosal melanomaSeminars in Cancer Biology, 2020
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2019
- Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targetsNature Communications, 2019
- Mucosal Melanoma: Epidemiology, Biology and Treatment2015